XTL Biopharmaceuticals Ltd ADR

Company Profile

XTL Biopharmaceuticals Ltd ADR had its IPO on 2005-09-01 under the ticker symbol XTLB.

The company operates in the LIFE SCIENCES sector and PHARMACEUTICAL PREPARATIONS industry. XTL Biopharmaceuticals Ltd ADR has a staff strength of 0 employees.

Stock update

Shares of XTL Biopharmaceuticals Ltd ADR opened at $1.23 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $1.23 - $1.23, and closed at $1.23.

This is a -4.65% slip from the previous day's closing price.

A total volume of 210 shares were traded at the close of the day’s session.

In the last one week, shares of XTL Biopharmaceuticals Ltd ADR have increased by +23%.

XTL Biopharmaceuticals Ltd ADR's Key Ratios

XTL Biopharmaceuticals Ltd ADR has a market cap of $0.007 billion, indicating a price to book ratio of 1.264 and a price to sales ratio of -.

In the last 12-months XTL Biopharmaceuticals Ltd ADR’s revenue was $0.000 billion with a gross profit of $0.000 billion and an EBITDA of $-0.001 billion. The EBITDA ratio measures XTL Biopharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, XTL Biopharmaceuticals Ltd ADR’s operating margin was 0% while its return on assets stood at -9.31% with a return of equity of 34.4%.

In Q2, XTL Biopharmaceuticals Ltd ADR’s quarterly earnings growth was a negative -76% while revenue growth was a positive 0%.

XTL Biopharmaceuticals Ltd ADR’s PE and PEG Ratio

Forward PE

-

Trailing PE

4.161

PEG

0

Its diluted EPS in the last 12-months stands at $0.31 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into XTL Biopharmaceuticals Ltd ADR’s profitability.

XTL Biopharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of - and a EV to EBITDA ratio of 29.64. Its price to sales ratio in the trailing 12-months stood at -.

XTL Biopharmaceuticals Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$0.000 billion

Total Liabilities

$0.000 billion

Operating Cash Flow

$0.000 billion

Capital Expenditure

$0.000 billion

Dividend Payout Ratio

0%

XTL Biopharmaceuticals Ltd ADR ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

XTL Biopharmaceuticals Ltd ADR ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

XTL Biopharmaceuticals Ltd ADR’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, XTL Biopharmaceuticals Ltd ADR's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, XTL Biopharmaceuticals Ltd ADR paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price

$1.23

52-Week High

$4.03

52-Week Low

$0.85

Analyst Target Price

$30

XTL Biopharmaceuticals Ltd ADR stock is currently trading at $1.23 per share. It touched a 52-week high of $4.03 and a 52-week low of $4.03. Analysts tracking the stock have a 12-month average target price of $30.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.